Harmony Biosciences price target raised to $75 from $71 at Cantor Fitzgerald

Cantor Fitzgerald raised the firm’s price target on Harmony Biosciences to $75 from $71 and keeps an Overweight rating on the shares. While Harmony reported Q1 revenue slightly below consensus, the increase in average patients on WAKIX of roughly 200 is in line with the firm’s estimate, the analyst tells investors in a research note. The firm views Q1 as a quarter of positive commercial execution despite the revenue miss.